Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3809740 | 1.00 | BRD4 (0.57) | BRD4ALDH1A1GLALMNAMAPT | |
| SCHEMBL3636618 | 0.87 | ALDH1A1 (0.54) | BRD4ALDH1A1GLALMNAMAPT | |
| SCHEMBL3859470 | 0.87 | ALDH1A1 (0.54) | BRD4ALDH1A1GLALMNAMAPT | |
| SCHEMBL6214817 | 0.86 | LMNA (0.55) | BRD4ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5205180 | 0.85 | TSHR (0.49) | BRD4ALDH1A1GLALMNAMAPT | |
| SCHEMBL3205373 | 0.85 | TSHR (0.49) | BRD4ALDH1A1GLALMNAMAPT | |
| SCHEMBL3806023 | 0.85 | TSHR (0.49) | BRD4ALDH1A1GLALMNAMAPT | |
| SCHEMBL3805824 | 0.84 | ALDH1A1 (0.51) | ALDH1A1GLAMAPTSMN1; SMN2RAB9A | |
| SCHEMBL7697711 | 0.84 | TSHR (0.56) | BRD4ALDH1A1GLALMNAMAPT | |
| SCHEMBL4805317 | 0.84 | TSHR (0.56) | BRD4ALDH1A1GLALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119570181-A | Fluoroplastic cable | 河北鑫昌龙电缆有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-116375995-B | High-barrier modified polylactic acid material and preparation method and application thereof | 万华化学（宁波）有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-113138531-B | Resin composition, cured film, and black matrix | 新应材股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119570181-A | Fluoroplastic cable | 河北鑫昌龙电缆有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-118276407-A | Photosensitive resin composition, cured film, and black matrix | 新应材股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-108342049-B | Physical split-phase dynamic polymer and application thereof | 厦门天策材料科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116375995-A | High-barrier modified polylactic acid material and preparation method and application thereof | 万华化学（宁波）有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-113138531-A | Resin composition, cured film, and black matrix | 新应材股份有限公司 | 2021-07-20 | — | — | CN | disclosed |
| CN-107556450-B | Dynamic polymer with hybrid cross-linked network and application thereof | 翁秋梅 | 2020-11-24 | — | — | CN | disclosed |
| US-20090306141-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2001062757-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| EP-1084114-A1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-1021434-A2 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND USE | Krenitsky Pharmaceuticals, Inc. (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0881907-A4 | CYCLIC PEPTIDE ANTIFUNGAL AGENTS | LILLY CO ELI (US) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999062890-A1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0881907-A1 | CYCLIC PEPTIDE ANTIFUNGAL AGENTS | ELI LILLY AND COMPANY (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998012190-A2 | PHENOXATHIIN DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE | KRENITSKY PHARMACEUTICAL, INC. (US) | 1998-03-26 | — | — | WO | disclosed |
| WO-1997027864-A1 | CYCLIC PEPTIDE ANTIFUNGAL AGENTS | ELI LILLY AND COMPANY (US) | 1997-08-07 | — | — | WO | disclosed |
| EP-0531382-A1 | N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1993-03-17 | — | — | EP | disclosed |
| WO-1991018888-A1 | N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306141-A1 | Novel Compounds | CHRM2, CHRM1, C1R | BRD4 847/4885ALDH1A1 1779/4885GLA 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.